AVR anteris technologies global corp.

AVR CEO interview on Proactive Investors, page-19

  1. 348 Posts.
    lightbulb Created with Sketch. 34
    Abbott has a massive problem to face from the degradation of the Trifecta valves implanted on its patients. Dr. Anita Asgar has chosen DurAVR over the other commercially available valves from Edwards and Medtronic says it all.
    Surely Abbott will take a good look at Anteris in particular as Abbott will be focusing on the tissue based valves development to fill the void from the withdrawal of its Trifecta valves. An opportunity too good to miss…

    Not advice, DYOR.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$6.05
Change
0.050(0.83%)
Mkt cap ! $93.76M
Open High Low Value Volume
$6.00 $6.06 $6.00 $29.76K 4.943K

Buyers (Bids)

No. Vol. Price($)
2 92 $6.00
 

Sellers (Offers)

Price($) Vol. No.
$6.14 2634 2
View Market Depth
Last trade - 13.46pm 24/06/2025 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.